Summary Gamma Therapeutics, Inc. (Gamma Therapeutics) is a biotechnology company which offers biopharmaceutical and diagnostic test solutions. The company's product portfolio encompasses GammaCoeur, Gammarin and GammaSeal. GammaCoeur is developed to address the need for a new cardiovascular disease risk assay and complement traditional testing methods such as total fibrinogen, cholesterol for heart attack and stroke risk. Gammarin, a non-immunogenic, anticoagulant is a pharmaceutical drug that is being developed for use in patients undergoing major surgery. GammaSeal, a high strength surgical sealant is being developed for areas of mechanical strain such as wound repair or large artery vascular surgery. Its products are developed based on its technology, Gamma Prime Fibrinogen, which is a natural occurring protein in human blood. Gamma Therapeutics is headquartered in Portland, Oregon, the US. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company Gamma Therapeutics, Inc. - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons To Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Gamma Therapeutics, Inc. Company Snapshot 5 Gamma Therapeutics, Inc. Company Overview 5 Gamma Therapeutics, Inc. Pipeline Products and Clinical Trials Overview 6 Gamma Therapeutics, Inc. - Pipeline Analysis Overview 8 Key Facts 8 Gamma Therapeutics, Inc. - Major Products and Services 9 Gamma Therapeutics, Inc. Pipeline Products by Development Stage 10 Gamma Therapeutics, Inc. Pipeline Products Overview 11 GammaMist 11 GammaMist Product Overview 11 GammaSeal 12 GammaSeal Product Overview 12 GammaTF 13 GammaTF Product Overview 13 Gamma Therapeutics, Inc. - Key Competitors 14 Gamma Therapeutics, Inc. - Key Employees 15 Gamma Therapeutics, Inc. - Locations And Subsidiaries 16 Head Office 16 Recent Developments 17 Gamma Therapeutics, Inc., Recent Developments 17 May 01, 2012: Gamma Therapeutics Awarded U.S. Provisional Patent 17 Apr 17, 2012: Gamma Therapeutics to Present GammaCoeur CVD Risk Assay 17 Jul 07, 2011: Gamma Therapeutics's Founder Awarded U.S. Patent 18 Apr 19, 2011: Gamma Therapeutics Awarded Phase II Research Grant 19 Feb 01, 2011: GT Appoints Prestigious Board of Science Advisors to Guide Product Development 19 Nov 18, 2010: Gamma Therapeutics Introduces New Cardiovascular Disease Test 20 Appendix 22 Methodology 22 About GlobalData 22 Contact Us 22 Disclaimer 22
List of Tables
Gamma Therapeutics, Inc. Pipeline Products and Clinical Trials Overview 6 Gamma Therapeutics, Inc. Pipeline Products by Equipment Type 6 Gamma Therapeutics, Inc. Pipeline Products by Indication 7 Gamma Therapeutics, Inc., Key Facts 8 Gamma Therapeutics, Inc., Major Products and Services 9 Gamma Therapeutics, Inc. Number of Pipeline Products by Development Stage 10 Gamma Therapeutics, Inc. Pipeline Products Summary by Development Stage 10 GammaMist - Product Status 11 GammaMist - Product Description 11 GammaSeal - Product Status 12 GammaSeal - Product Description 12 GammaTF - Product Status 13 GammaTF - Product Description 13 Gamma Therapeutics, Inc., Key Employees 15
List of Figures
Gamma Therapeutics, Inc. Pipeline Products by Equipment Type 7 Gamma Therapeutics, Inc. Pipeline Products by Development Stage 10
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposableRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.